Clinical Trial Update: Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating infliximab to improve retention of the Boston Keratoprosthesis in patients after Stevens-Johnson Syndrome/Toxic Epidermal Necrolys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Blindness
• Stevens-johnson Syndrome

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Stevens-Johnson Syndrome, Corneal Blindness | Phase 1, Phase 2 | Status: WITHDRAWN